Dario Announces Complete Integration of Twill Capabilities Across Full Multi-Condition Platform
- Integration of behavioral health and wellbeing solutions with navigation and engagement technology creates the most comprehensive solution in the market under the Dario brand NEW YORK , Oct. 17, 2024 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a global leader in digital health, today announces the full integration of Twill's advanced behavioral health and navigation capabilities into the Dario platform. The integration completes Dario's effort to create one of the most comprehensive and effective end-to-end digital health solutions in the market.
- 10/17/2024
|
Twill by Dario to Offer a Benefit for AARP Members
- New offer gives Dario access to millions of AARP members, enabling engagement with people over 50 in health and well-being beginning in January 2025 NEW YORK , Oct. 15, 2024 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, announced today a new AARP member benefit that provides members with proven digital behavioral health and well-being solutions from Twill by Dario. The new benefit is expected to launch in January of 2025 for AARP members.
- 10/15/2024
|
All You Need to Know About DarioHealth (DRIO) Rating Upgrade to Strong Buy
- DarioHealth (DRIO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
- 10/02/2024
|
Bet on 5 Top-Ranked Stocks With Rising P/E
- Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach. These stocks include Adverum Biotechnologies (ADVM), IceCure Medical (ICCM), DarioHealth (DRIO), Energous (WATT) and Virgin Galactic (SPCE).
- 10/02/2024
|
National Medicare Health Plan Partners with Twill by Dario to Promote Healthy Aging with New Digital Mental Health Benefits for Seniors
- The new contract significantly expands Dario's footprint with more than a million eligible members beginning January 2025 NEW YORK , Oct. 1, 2024 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, announced today a new contract with a national Medicare Advantage health plan (the "Plan") to launch its behavioral health solution for the Plan members beginning in January 2025. This new contract marks the beginning of a strategic relationship, starting with Dario's behavioral health solution, Twill by Dario, in 2025 and potentially expanding to additional Dario solutions in 2026 and beyond.
- 10/01/2024
|
Bet on 5 Top-Ranked Stocks With Rising P/E for Stellar Gains
- Tap five stocks with increasing P/E ratios. These stocks include TAL Education Group (TAL), The RealReal (REAL), DarioHealth (DRIO), HealthEquity (HQY) and Energous (WATT).
- 09/18/2024
|
DarioHealth And 2 Other Stocks Under $5 Executives Are Buying
- The Dow Jones index closed higher by more than 200 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects.
- 09/13/2024
|
Dario Introduces Integration of Twill Behavioral Health Capabilities into Cardiometabolic Health Solution to Enhance Member Engagement and Outcomes
- The integration of Twill's condition-specific, expert-led peer groups will enhance the member experience and deepen engagement with Dario's proven cardiometabolic solution NEW YORK , Sept. 12, 2024 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital health market announced today the integration of condition-specific communities and peer groups with personalized navigation capabilities into its cardiometabolic solution to improve outcomes-based engagement, marking a significant milestone in the integration of the Dario-Twill product offering.
- 09/12/2024
|
Dario Publishes New Research Revealing How Physical Activity Mediates the Impact of Depression on Blood Glucose Levels in Individuals with Diabetes or Prediabetes
- New Research Confirms the Benefit of Dario's Integrated, Data-Driven Approach to Health and Chronic Condition Management NEW YORK , Sept. 10, 2024 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital health market announced today the publication of a new study in the peer-reviewed journal Frontiers in Endocrinology.
- 09/10/2024
|
DarioHealth Corp. (DRIO) Q2 2024 Earnings Call Transcript
- DarioHealth Corp. (NASDAQ:DRIO ) Q2 2024 Results Conference Call August 8, 2024 8:30 AM ET Company Participants Kat Parrella - Investor Relations Manager Erez Raphael - Chief Executive Officer Steven Nelson - Chief Commercial Officer Conference Call Participants Lucas Romanski - TD Cowen Operator Good morning, ladies and gentlemen, and welcome to the DarioHealth Second Quarter 2024 Results Conference Call. At this time, all lines are in a listen-only mode.
- 08/10/2024
|
DarioHealth Corp. (DRIO) Q2 Earnings Beat Estimates
- DarioHealth Corp. (DRIO) came out with quarterly earnings of $0.06 per share, beating the Zacks Consensus Estimate of a loss of $0.29 per share. This compares to loss of $0.58 per share a year ago.
- 08/08/2024
|
DarioHealth Reports Second Quarter 2024 Financial and Operating Results
- Q2 revenue of $6.26 million reflects an increase of 8.6% over Q1 2024, and an increase of 1.7% over Q2 of 2023, driven primarily by increased B2B2C revenues Q2 commercial and consumer revenues totaled $7.34 million before a non-recurring price concession in collaboration with a pharma partner, compared to $3.57 million for Q2 of 2023, representing a 105% increase Core B2B2C revenue channel, recurring revenues from employers and health plans in the second quarter totaled $5.5 million, an increase of 315% year over year and 60% sequentially from the first quarter of 2024 Made progress on collaboration with existing and potential pharma clients to accelerate a transformation to a new, recurring, and more stable revenue-based business model in our pharma channel, which is currently milestone based. Strong business momentum on cross selling of Twill offering to Dario clients with at least 10 initial clients Executed on Dario-Twill synergies that expect to reduce operating expenses by approximately 40% by Q1 2025 compared to Q1 2024, aiding in an expected reduction in operating losses of at least 70% by Q1 2025 Saw increased GLP-1 product adoption across new and existing clients seeking our metabolic solutions, with 9 clients implementing already and several more expected in 2024.
- 08/08/2024
|
DarioHealth to Report Second Quarter 2024 Results on Thursday, August 8th
- Company to host conference call and webcast at 8:30am ET NEW YORK , July 30, 2024 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market, announced today that it will release its financial results for the 2nd quarter ended June 30th, 2024, on Thursday, August 8th, 2024, before the market opens and will host a conference call and webcast at 8:30 am Eastern Time. Erez Raphael, Chief Executive Officer, and Steven Nelson, Chief Commercial Officer, will host the call.
- 07/30/2024
|
Dario Expands GLP-1 Solution Client Base with New Employer Contract
- Dario's leading behavior change solutions continue to win interest in the employer, payer and pharmaceutical markets NEW YORK , July 16, 2024 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, announced today a new contract with a national employer to provide its cardiometabolic solution with integrated support for GLP-1s to employees beginning in the third quarter of 2024. The employer, a leader in environmental services, selected Dario's cardiometabolic suite to address multiple health conditions, including diabetes, pre-diabetes, hypertension and weight management needs, including integrated support for those employees taking a GLP-1 medication.
- 07/16/2024
|
Dario Demonstrates 12 Months of Sustained Healthy Behavior Change for Members Taking a GLP-1
- New research confirms behavior change driven by Dario digital platform is sustainable for 12 month period and supports clinical results for members taking a GLP-1 Additional research demonstrates 31% of Dario members with Type 2 diabetes achieve results reflecting diabetes remission NEW YORK , June 25, 2024 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, announced today two new studies presented this past weekend at the 84th Annual American Diabetes Association (ADA) Scientific Sessions in Orlando. The first study provides an analysis of member data for those tracking a GLP-1 medication in Dario's cardiometabolic solution.
- 06/25/2024
|
3 Small-Cap AI Stocks to Buy Now: June 2024
- While the innovation sphere constantly focuses on artificial intelligence these days, the top players in the field have gotten a lot of attention – maybe too much attention. Recently, we've seen the mighty Nvidia (NASDAQ: NVDA ) lose a step from its previously mercurial ways.
- 06/25/2024
|
Empowering Commercial Expansion: DarioHealth Announces Strategic Reorganization and Appoints Inaugural Chief Commercial Officer
- After two decades of successfully scaling multiple healthcare companies, Steven Nelson joins DarioHealth as Chief Commercial Officer to accelerate revenue growth across the health plans, employers and pharma channels NEW YORK , June 5, 2024 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario", "DarioHealth" or the "Company"), a leader in the global digital health market, announced today a strategic reorganization designed to streamline leadership and focus the organization on accelerating its commercialization efforts. This move reflects the Company's commitment to bringing its innovative solutions to the market faster, maximizing customer impact, and driving the organization to profitability.
- 06/05/2024
|
DarioHealth Corp. (DRIO) Reports Q1 Loss, Misses Revenue Estimates
- DarioHealth Corp. (DRIO) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.59. This compares to earnings of $0.45 per share a year ago.
- 05/15/2024
|
DarioHealth Reports First Quarter 2024 Financial and Operating Results
- First quarter revenue of $ 5.8 million reflects an increase of 59% over fourth quarter of 2023 primarily resulting from an increase in B2B2C revenues and reflects a decrease of 18.5% compared to the first quarter of 2023 due to milestone driven revenues. Core revenue channel B2B2C, employers and health plans recurring revenues in the first quarter totaled $3.47 million, an increase of 176% year over year and 210% sequentially from $1.12 million in the fourth quarter 2023 as the core business continues to gain traction, as well as the addition of Twill Inc. revenues post February 15 th closing Launched the Aetna platform generating revenue in Q1 2024 as Aetna continues to add employers to the platform Accelerated path to profitability through growing revenues in the B2B2C channel which represents proforma of $22M in annual recurring revenue ("ARR") Executing on Dario-Twill synergies that we expect to reduce operating expenses by 30% by the fourth quarter of 2024 Company anticipates reaching a breakeven run rate in the second half of 2025 Ended Q1 2024 with cash equivalents of $34.7 million Company to host investor conference call and webcast at 8:30 a.m.
- 05/15/2024
|
DarioHealth to Report First Quarter 2024 Results on Wednesday, May 15th
- Company to host conference call and webcast at 8:30am ET NEW YORK , May 7, 2024 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market, announced today that it will release its financial results for the 1st quarter ended March 31st, 2024, on Wednesday, May 15th, 2024, before the market opens and will host a conference call and webcast at 8:30 am Eastern Time. Erez Raphael, Chief Executive Officer and Rick Anderson, President, will host the call.
- 05/07/2024
|
Dario Publishes New Peer-Reviewed Study that Deepens the Body of Evidence that Managing Cardiometabolic Conditions in One Integrated Platform Improves Clinical Outcomes
- Quasi-randomized study demonstrates the value of Dario's integrated approach to provide one solution for members to manage diabetes, pre-diabetes, blood pressure, weight and taking a GLP-1 NEW YORK , April 25, 2024 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, announced today new research published in the leading peer-reviewed journal for digital health and medicine, Journal of Internet Medicine (JMIR) demonstrating a clinically significant reduction in blood glucose levels for members using Dario to manage weight alongside diabetes. More than 80% of people living with Type 2 diabetes are overweight and the two conditions are closely linked to the same underlying unhealthy behaviors.
- 04/25/2024
|
Dario Signs Two Employers for Cardiometabolic Suite with Integrated GLP-1 Solution
- Dario selected to provide integrated and proven solutions to improve employee cardiometabolic health NEW YORK , April 18, 2024 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, announced today two new contracts to provide integrated chronic condition management solutions for two employers beginning in the second quarter of 2024. The employers, a national supply chain company and a regional education organization, selected Dario's cardiometabolic suite to help improve outcomes for employees with cardiometabolic health conditions, including diabetes, pre-diabetes, hypertension and weight management needs, including support for individuals taking a GLP-1 medication.
- 04/18/2024
|
Dario Publishes Two New Peer-Reviewed Studies Demonstrating Impact of Digital Behavioral Health
- Studies include a Randomized Controlled Trial demonstrating significant reduction in perceived stress for teens NEW YORK , April 10, 2024 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, announced today two new studies published in the leading peer-reviewed journal for digital health and medicine, Journal of Internet Medicine (JMIR), including a Randomized Controlled Trial (RCT) demonstrating the impact of a digital stress reduction program for teens. Digital Tools Reduce Stress and Brooding in Teens in a Randomized Control Trial The first study uses the gold standard in research, a randomized controlled clinical trial (RCT), to demonstrate the impacts of a self-guided Digital Mental Health Intervention (DMHI) for teens.
- 04/10/2024
|
Two National Employers Select Dario's Integrated Chronic Condition Solution to Improve Employee Health
- Dario selected to provide integrated approach to improve employee cardiometabolic health - including support for those taking a GLP-1 medication - musculoskeletal and behavioral health NEW YORK , April 2, 2024 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, announced today two new contracts to provide integrated chronic condition management solutions for two national employers beginning in the second quarter of 2024. The first employer, a global private investment group, selected Dario's cardiometabolic suite to help improve outcomes for employees with cardiometabolic health conditions, including diabetes, pre-diabetes, hypertension and weight management needs, including support for individuals taking a GLP-1.
- 04/02/2024
|
DarioHealth Corp. (DRIO) Q4 2023 Earnings Call Transcript
- DarioHealth Corp. (DRIO) Q4 2023 Earnings Call Transcript
- 03/28/2024
|
DarioHealth Reports Fourth Quarter and Full-Year 2023 Financial and Operating Results
- Full-year 2023 revenue of $20.4 million reflects a decrease from 2022 revenue of $7.3 due to a managed decrease in B2C and strategic milestone revenue as the core B2B2C revenue increased. 2023 B2B2C, employers and health plans recurring revenues increased 39% year over year as the core business continues to gain traction.
- 03/28/2024
|
DARIOHEALTH TO REPORT FOURTH QUARTER 2023 RESULTS ON THURSDAY, MARCH 28TH
- Company to host conference call and webcast at 8:30am ET NEW YORK , March 21, 2024 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market, announced today that it will release its financial results for the 4th quarter ended December 31, 2023, on Thursday, March 28th, 2024, before the market opens and will host a conference call and webcast at 8:30 am Eastern Time. Erez Raphael, Chief Executive Officer and Rick Anderson, President, will host the call.
- 03/21/2024
|
New Research from Dario Demonstrates Ability to Deliver Improved Health Outcomes with Integrated Solution for Members Managing Weight and Blood Glucose with or without GLP-1 Medications
- Study presented at ATTD 2024 is the first of a planned series examining the impact of Dario's integrated cardiometabolic solution as a means to address weight and diabetes with or without a GLP-1 Additional research presented demonstrated Dario's ability to improve awareness of the importance of flu vaccines in member with Type 2 diabetes NEW YORK , March 12, 2024 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) (the "Company"), a leader in the global digital therapeutics (DTx) market, announced today two new clinical studies presented at the 17th International Conference on Advanced Technologies and Treatments for Diabetes (ATTD) 2024, held March 6 – 9 in Florence, Italy. Examining evolving standards for metabolic health: Improving outcomes with or without medication The introduction of GLP-1s as an effective tool for both weight loss and diabetes management is evolving the standards of care for metabolic health conditions.
- 03/12/2024
|
DARIOHEALTH TO PARTICIPATE IN THE COWEN 43RD ANNUAL HEALTHCARE CONFERENCE
- NEW YORK, Feb. 28, 2024 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital health market, today announced that management will participate in the Cowen 44th Annual Healthcare Conference, which is being held March 4-6, 2024, at the Boston Marriott Copley Place in Boston, Massachusetts. Erez Raphael, Chief Executive Officer, and Rick Anderson, President, will participate in a fireside chat on Wednesday, March 6th, from 10:30 – 11:00 AM ET.
- 02/28/2024
|
DARIOHEALTH TO PARTICIPATE IN THE COWEN 43RD ANNUAL HEALTHCARE CONFERENCE
- NEW YORK , Feb. 28, 2024 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital health market, today announced that management will participate in the Cowen 44th Annual Healthcare Conference, which is being held March 4-6, 2024, at the Boston Marriott Copley Place in Boston, Massachusetts. Erez Raphael, Chief Executive Officer, and Rick Anderson, President, will participate in a fireside chat on Wednesday, March 6th, from 10:30 – 11:00 AM ET.
- 02/28/2024
|
Dario acquires Twill creating one of the most comprehensive digital health platform across the most prevalent chronic conditions
- Expecting nearly doubling Dario's pro forma revenues in 2023 Acquisition is immediately accretive to revenue and gross margins and expected to accelerate path to profitability Concurrent with the acquisition Dario prices $22.4 million equity financing Company to host conference call today at 8:30am ET. Dial-in and replay information below NEW YORK , Feb. 21, 2024 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company") announced today that it has acquired Twill, Inc. ("Twill"), a leader in digital-led care.
- 02/21/2024
|
Regional Union Selects Dario's Cardiometabolic Solution for Diabetes, Hypertension, Weight Management and GLP-1 Support
- Dario's integrated solution to support improved whole health gains traction in public and labor market NEW YORK , Jan. 11, 2024 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, announced today a new contract to provide its cardiometabolic solution to a regional union (the "Union"), expected to begin in the first quarter of 2024. The Union, representing food industry workers, selected Dario to deliver integrated support for employees living with diabetes, pre-diabetes and weight management needs along with special support for those taking a GLP-1, or anti-obesity medication.
- 01/11/2024
|
National Employer Selects Dario Cardiometabolic and GLP-1 Solutions to Improve Employee Health
- New client will use Dario's integrated approach to support long-term behavior change for employees living with diabetes, pre-diabetes, hypertension and those taking a GLP-1 medication NEW YORK , Dec. 5, 2023 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, announced today a new contract to provide cardiometabolic and GLP-1 solutions to a national employer (the "Employer") beginning in January 2024. The Employer, a national logistics company, selected Dario to deliver integrated support for employees living with diabetes, pre-diabetes, weight management and hypertension, while also providing a tailored experience for employees taking a GLP-1 medication.
- 12/05/2023
|
Blue Shield of California's Award-Winning Wellvolution Now More Accessible for Spanish Speakers, Adds New Hypertension Offering
- Nonprofit health plan expands services to better meet the healthcare needs of Californians by making it easier to enroll in lifestyle medicine programs at no additional cost OAKLAND, Calif. , Nov. 29, 2023 /PRNewswire/ -- Blue Shield of California is making its award-winning digital health platform Wellvolution more accessible for Spanish-speakers and expanding its program with the addition of Dario, an at-home solution for high blood pressure, or hypertension, that combines personalized health coaching and tech-enabled monitoring.
- 11/29/2023
|
Dario Contracts with New Employer for Cardiometabolic Solution
- Demand for Dario's integrated cardiometabolic solution continues to grow as employers grappling with the surge in GLP-1 medication utilization search for proven ways to change health behaviors NEW YORK , Nov. 27, 2023 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, announced today a new contract to provide its cardiometabolic solution to an employer (the "Employer") beginning in January 2024. The Employer, a national financial and business services company, selected Dario to improve the cardiometabolic health of its population with an integrated solution for diabetes, pre-diabetes, weight management and hypertension along with tailored support for employees taking a GLP-1, or anti-obesity, medications.
- 11/27/2023
|
New Research Sheds Light on Mediators of Improved Outcomes in Dario Users
- Two new analyses associate improved clinical and economic outcomes with use of Dario's digital health solution NEW YORK , Nov. 21, 2023 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, announced today two new analyses recently presented by Sanofi U.S. demonstrating two mediators associated with improved clinical and economic in Dario users. Improved Clinical Outcomes Linked with Improved Medication Adherence Presentations by Sanofi U.S. at the Diabetes Technology Society (DTS) annual conference, held Nov. 2 – 4, examined real-world data from matched Dario users and non-users with type 2 diabetes to determine the association of medication adherence from Dario's digital health solution with blood glucose control.
- 11/21/2023
|
Dario Publishes New Research Demonstrating that Dario Users That Increased Physical Activity Can Maintain Reduced Blood Glucose
- New study highlights the value of a whole health approach managing chronic conditions and supporting members using GLP-1s NEW YORK , Nov. 13, 2023 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, announced new research presented at the Diabetes Technology Society 2023 Meeting on November 7, 2023. The new research demonstrated the value of associating physical activity tracking alongside blood sugar tracking for people living with diabetes and pre-diabetes.
- 11/13/2023
|
DarioHealth Disappoints, But A Better Future Is Ahead
- DarioHealth has experienced a disappointing year with stalled revenue growth and a decline in new customer wins. However, H2/23 and FY24 are expected to bring improved financials, including revenue growth, expanded gross margins, and declining operating expenses. The company's competitive advantages include a customer-friendly platform, a multi-condition platform, and partnerships with important industry players.
- 10/03/2023
|
DarioHealth is an AI-Powered Digital Therapeutics Play
- DarioHealth Co. NASDAQ: DRIO is an AI-powered digital therapeutics platform and provider that adaptively personalizes monitoring and treatments for chronic diseases. The mobile app manages five common comorbidity conditions, including diabetes, weight loss, hypertension, musculoskeletal and behavioral health, across six domains: timing, tone, channel, content, frequency and intervention.
- 06/13/2023
|
DarioHealth Corp. (DRIO) Q1 2023 Earnings Call Transcript
- DarioHealth Corp. (NASDAQ:DRIO ) Q1 2023 Earnings Conference Call May 11, 2023 8:30 AM ET Company Participants Chuck Padala - Managing Director, Investor Relations Erez Raphael - Chief Executive Officer Rick Anderson - President Conference Call Participants Alex Nowak - Craig-Hallum Capital Group Charles Rhyee - Cowen Rahul Rakhit - LifeSci Capital Benjamin Haynor - Alliance Global Partners David Grossman - Stifel Financial Operator Good morning, and welcome to the DarioHealth First Quarter 2023 Results Call. All participants are in a listen only mode [Operator Instructions] After today's presentation, there will be opportunity to ask questions.
- 05/11/2023
|
DarioHealth Corp. (DRIO) Q4 2022 Results Conference Call
- DarioHealth Corp. (NASDAQ:DRIO ) Q4 2022 Results Conference Call March 9, 2023 8:30 PM ET Company Participants Glenn Garmont - Investor Relations Erez Raphael - Chief Executive Officer Rick Anderson - President Conference Call Participants Charles Rhyee - TD Cowen Alexander Nowak - Craig-Hallum Capital Group Rahul Rakhit - LifeSci Capital Ben Haynor - Alliance Global Partners David Grossman - Stifel Operator Greetings, and welcome to the DarioHealth Fourth Quarter 2022 Results Call. At this time, all participants are in a listen only mode.
- 03/09/2023
|
DarioHealth to Report Fourth Quarter 2022 Results on Thursday, March 9th
- Company to host conference call and webcast at 8:30 am ET NEW YORK , March 2, 2023 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO), a leader in the global digital therapeutics (DTx) market, today announced it would release its financial results for the fourth quarter and year ended December 31, 2022, on Thursday, March 9, 2023, before market opens and will host a conference call and webcast at 8:30 am Eastern Time. Erez Raphael, Chief Executive Officer, Rick Anderson, President, and Zvi Ben-David, Chief Financial Officer will host the call.
- 03/02/2023
|
DarioHealth: January Rally Looks To Be Exhausting (Technical Analysis)
- DarioHealth rallied off a low in December and since raced to new highs. Market generated data suggests the rally could extend over the coming weeks to months.
- 02/02/2023
|
DarioHealth: Market Sentiment Shift Post Q3 Numbers, Revise To Speculative Buy
- We've revised our rating on DarioHealth to a buy, with consideration to tactical allocation for equity portfolios. DRIO's Q3 numbers came in strong with upsides versus consensus at the top and bottom lines.
- 11/17/2022
|
DarioHealth Corp. (DRIO) Q3 2022 Earnings Call Transcript
- DarioHealth Corp. (NASDAQ:DRIO ) Q3 2022 Results Conference Call November 15, 2022 8:30 AM ET Company Participants Glenn Garmont - IR Erez Raphael - CEO Rick Anderson - President Conference Call Participants Charles Rhyee – Cowen Rahul Rakhit - LifeSci Capital David Grossman – Stifel Ben Haynor - Alliance Global Partners Chase Knickerbocker - Craig-Hallum Operator Good day, everyone, and welcome to the DarioHealth Third Quarter 2022 Results Conference Call. [Operator Instructions] Please note, this event is being recorded.
- 11/15/2022
|
DarioHealth Corp (DRIO) CEO Erez Raphael on Q2 2022 Results - Earnings Call Transcript
- DarioHealth Corp (NASDAQ:DRIO ) Q2 2022 Earnings Conference Call August 15, 2022 8:30 AM ET Company Participants Glenn Garmont - LifeSci Advisors Erez Raphael - CEO & Director Richard Anderson - President & GM, North America Conference Call Participants Charles Rhyee - Cowen and Company Alexander Nowak - Craig-Hallum Rahul Rakhit - LifeSci Capital David Grossman - Stifel, Nicolaus & Company Benjamin Haynor - Alliance Global Partners Nathan Weinstein - Aegis Capital Corporation John Vandermosten - Zacks Small-Cap Research Operator Greetings, and welcome to the DarioHealth Corp. Second Quarter 2020 Results Conference Call. [Operator Instructions].
- 08/15/2022
|
Dario Health (DRIO) Poised To Inflect Upon Full Launch of National Health Plan
- Dario Health (DRIO) Poised to Inflect Upon Full Launch of National Health Plan - Fundamentals: Company positioned to avoid dilutive financing after recent $50M credit facility with OrbiMed - Catalysts: Company is guiding for a full launch of a large national insurer, by end of June -.
- 06/15/2022
|
DarioHealth Corp. (DRIO) CEO Erez Raphael on Q1 2022 Results - Earnings Call Transcript
- DarioHealth Corp. (NASDAQ:DRIO ) Q1 2022 Earnings Conference Call May 12, 2022 8:30 AM ET Company Participants Glenn Garmont - Investor Relations Erez Raphael - Chief Executive Officer Rick Anderson - President & General Manager, North America Conference Call Participants Charles Rhyee - Cowen Rahul Rakhit - LifeSci Capital Nathan Weinstein - Aegis Capital John Vandermosten - Zacks David Grossman - Stifel Operator Good morning and welcome to the DarioHealth First Quarter 2022 Results Call. all participants will be in listen-only mode.
- 05/12/2022
|
DarioHealth's (DRIO) CEO Erez Raphael on Q4 2021 Results - Earnings Call Transcript
- DarioHealth's (DRIO) CEO Erez Raphael on Q4 2021 Results - Earnings Call Transcript
- 03/22/2022
|
DarioHealth: Moving Towards An Inflection Point
- After starting its B2B2C program last year, DarioHealth should finally start to see organic growth in revenues as the company starts to implement its solutions within a large health plan. The company has continued to grow its prospective pipeline despite signing a record amount of new customers within the last few months.
- 11/30/2021
|
DarioHealth Corp. (DRIO) CEO Erez Raphael on Q3 2021 Results - Earnings Call Transcript
- DarioHealth Corp. (DRIO) CEO Erez Raphael on Q3 2021 Results - Earnings Call Transcript
- 11/16/2021
|
Recap: DarioHealth Q3 Earnings
- DarioHealth (NASDAQ:DRIO) reported its Q3 earnings results on Monday, November 15, 2021 at 04:30 PM. Here's what investors need to know about the announcement.
- 11/15/2021
|
DarioHealth Earnings Preview
- DarioHealth (NASDAQ:DRIO) is set to give its latest quarterly earnings report on Monday, 2021-11-15. Here's what investors need to know before the announcement.
- 11/12/2021
|
DarioHealth to Report Third Quarter 2021 Results on Monday, November 15
- NEW YORK, Nov. 8, 2021 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO), a pioneer in the global digital therapeutics market, today announced it would release its financial results for the third quarter ended September 30, 2021 on Monday, November 15, 2021, after the close of trading. The company will host a conference call and webcast on Tuesday, November 16, at 8:30 am Eastern Time.
- 11/08/2021
|
DarioHealth to Participate in Upcoming Investor Conferences
- NEW YORK, Nov. 5, 2021 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics market, today announced that management will participate at the following conferences: Credit Suisse 30th Annual Healthcare Conference Format: Investor one-on-one meetingsDate: Tuesday, November 9, 2021 Live Fireside Chat with Erez Raphael, Chief Executive Officer of DarioHealth: 9:40 am EST Craig-Hallum 12th Annual Alpha Select Conference Format: Investor one-on-one meetingsDate: Tuesday, November 16, 2021 Interested parties can access the live and archived webcast of the Credit Suisse presentation on the Events and Presentations section of Dario's Investors website, https://dariohealth.investorroom.com/. About DarioHealth Corp. DarioHealth Corp. (NASDAQ: DRIO) is a leading global digital therapeutics company revolutionizing how people with chronic conditions manage their health.
- 11/05/2021
|
DarioHealth Unveils its Digital Musculoskeletal Solution Dario Move at HLTH 2021
- BOSTON, Oct. 18, 2021 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market, announced today the launch of Dario Move, a new digital physical therapy solution to manage common musculoskeletal (MSK) conditions that drive significant costs for employers and health plans. The solution is being unveiled at HLTH 2021, one of the largest and most important conferences for health innovation, which is taking place in a hybrid format (in-person and virtual) from October 17-20 in Boston.
- 10/18/2021
|
DRIO Stock: Why It Increased Today
- The stock price of DarioHealth Corp (NASDAQ: DRIO) increased by over 10% pre-market today. This is why it happened.
- 10/14/2021
|
DarioHealth Announces Agreement with Leading National Health Plan
- NEW YORK, Oct. 14, 2021 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market, announced today it has entered into an agreement with one of the largest U.S. national health plans ("Plan") to offer its self-insured employer customers the Dario digital behavioral health solution as part of its behavioral health offering. Initial members are expected on the platform in the fourth fiscal quarter of 2021, with additional rollout anticipated over the course of 2022.
- 10/14/2021
|
DarioHealth Announces Agreement with Global Employer for Metabolic and Musculoskeletal Health Solutions
- NEW YORK, Oct. 7, 2021 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market, announced today an agreement with a global company based in the United States ("Company") to provide its integrated digital health management solution for diabetes, hypertension, and musculoskeletal (MSK) health. The contract is expected to launch in the first quarter of 2022.
- 10/07/2021
|
DarioHealth to Participate in the Cantor Fitzgerald Virtual Global Healthcare Conference
- NEW YORK, Sept. 24, 2021 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics market, today announced that management will participate in a fireside chat during the Cantor Fitzgerald Virtual Global Healthcare Conference, which is being held September 27-30, 2021.
- 09/24/2021
|
DarioHealth Chief Medical Officer Dr. Omar Manejwala to Speak at American Health Insurance Plans National Conference on Medicare, Medicaid and Dual Eligibles
- NEW YORK, Sept. 17, 2021 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics market, today announced that the company's Chief Medical Officer, Dr. Omar Manejwala, will present at the annual American Health Insurance Plans National Conference on Medicare, Medicaid and Dual Eligibles being held virtually on September 22 nd, 2021 at 12:45 p.m.
- 09/17/2021
|
DarioHealth Chosen by Northeast Regional Employer
- Dario Continues to Expand its Employer Contracts Across Broad Range of Solutions NEW YORK, Sept. 9, 2021 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market, announced today that it has entered into an agreement to provide its suite of digital therapeutics for diabetes, hypertension and pre-diabetes to a Northeast regional employer ("Employer").
- 09/09/2021
|
DarioHealth Selected by Another Employer for Behavioral Health Services
- NEW YORK, Sept. 8, 2021 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market, announced today that it has entered into an agreement to provide its digital behavioral health platform to a casino resort company ("Casino Resort Company") in California.
- 09/08/2021
|
InvestorNewsBreaks – DarioHealth Corp. (NASDAQ: DRIO) Partners With Regional Primary Care Provider PeopleOne Health To Provide Digital Health Solutions
- DarioHealth (NASDAQ: DRIO), a pioneer in the global digital therapeutics market, has finalized a contract with PeopleOne Health to be the digital behavioral health solution of choice for patients effective in September 2021. PeopleOne Health is a regional care provider, and Dario's partnership with the company marks the company's continued expansion and growth in the provider market as it leverages its compelling proprietary product portfolio.
- 08/31/2021
|
DarioHealth Corp. (DRIO) CEO Erez Raphael on Q2 2021 Results - Earnings Call Transcript
- DarioHealth Corp. (DRIO) CEO Erez Raphael on Q2 2021 Results - Earnings Call Transcript
- 08/16/2021
|
Why Is DarioHealth Falling After Earnings?
- DarioHealth Corp (NASDAQ: DRIO) reported second-quarter FY21 revenue growth of 194% year-on-year to $5.26 million, beating the analyst consensus of $5.11 million. The non-GAAP billings rose 186% Y/Y to $5.13 million from higher sales and the consolidation of Upright revenues.
- 08/16/2021
|
Recap: DarioHealth Q2 Earnings
- Shares of DarioHealth (NASDAQ:DRIO) fell 0.5% in pre-market trading after the company reported Q2 results. Quarterly Results Earnings per share were unchanged 0.00% over the past year to ($0.68), which beat the estimate of ($0.85).
- 08/16/2021
|
DarioHealth Reports Strong Second Quarter 2021 Results and Operational Highlights
- NEW YORK, Aug. 16, 2021 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics market, today reported financial results for the second quarter of 2021 and provided a corporate and commercial update. "During the second quarter and subsequent period, we saw increasing demand for our integrated multi condition digital therapeutics solution, driven in part by the expansion of our metabolic offering into musculoskeletal and pain conditions through the acquisition of Upright Technologies in February 2021 and into behavioral health through the acquisition of wayForward in June 2021," stated Erez Raphael, Chief Executive Officer of Dario.
- 08/16/2021
|
DarioHealth Presents New Study Demonstrating Significant Clinical Impact of Personalized Digital Interventions Based on Real-Time Data
- NEW YORK, Aug. 12, 2021 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics market, today announced a new study at the American Association of Diabetes Care and Education Specialists (ADCES) annual conference demonstrating the impact of Dario's intelligent personalization platform. Dario's latest presentation examined the impact of personalized clinical interventions delivered in real-time through the company's digital therapeutics platform.
- 08/12/2021
|
DarioHealth Launches Behavioral Health Solutions Globally in New Partnership with Workplace Options
- NEW YORK, July 27, 2021 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO), a pioneer in the global digital therapeutics market, today announced the launch of its digital behavioral health solution that now includes Workplace Options (WPO) services for its global users. WPO is the largest independent provider of integrated employee wellbeing solutions around the world.
- 07/27/2021
|
DarioHealth Chief Medical Officer Omar Manejwala, M.D., to Present on the Role of Digital Therapeutics in Post-Pandemic Healthcare at DTx Europe
- NEW YORK , July 13, 2021 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market, announced Chief Medical Officer Omar Manejwala, M.D. will present "Rebalancing: Digital Therapeutics in a Post-Pandemic Healthcare System" during the virtual conference DTx Europe on July 14 th at 5:55 a.m.
- 07/13/2021
|
New Research from DarioHealth Expands Evidence that Personalized Interventions Impact Health Behaviors and Improve User Engagement
- NEW YORK, June 29, 2021 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market, presented new clinical research today at the American Diabetes Association (ADA) 81st Scientific Sessions, the premier diabetes conference for cutting-edge research and advances in diabetes care. Dario's latest research examines the impacts of the company's artificial intelligence (AI)-driven personalization engine on user engagement and clinical outcomes for close to 10,000 members.
- 06/29/2021
|
DarioHealth Remote Patient Monitoring Selected by Coastal Family Health Center to Improve Health of Patients with Hypertension
- NEW YORK, June 24, 2021 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics market, today announced it has been selected as digital health provider by Coastal Family Health Center, a local, non-profit healthcare network providing comprehensive primary care to patients across several underserved counties in and around the Mississippi Gulf Coast. The initial focus of the engagement will be Dario's Remote Patient Monitoring (RPM) solution for hypertension and the prevention of related cardiac events.
- 06/24/2021
|
DarioHealth Expands Footprint in Musculoskeletal Sensor Technologies with the Upright GO S
- NEW YORK, June 16, 2021 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO), a leader in the global digital therapeutics (DTx) market, announced today the launch of the Upright GO S, a new wearable sensor based on the company's pioneering biofeedback technologies to make better back health accessible to more people. This new product from Upright, by Dario, is part of the company's planned growth strategy for increasing platform membership across both business partnerships and consumer channels.
- 06/16/2021
|
DarioHealth to be Added to Russell 2000® and 3000® Indexes
- NEW YORK, June 15, 2021 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics market, today announced it is set to join the broad-market Russell 3000® Index and the small-cap Russell 2000® Index at the conclusion of the Russell U.S. Indexes annual reconstitution, effective after the US equity markets open on Monday, June 28, 2021, according to a preliminary list of additions posted by FTSE Russell on Friday, June 4, 2021. Annual reconstitution of the Russell indexes captures the 4,000 largest U.S. stocks as of May 7, 2021, ranking them by total market capitalization.
- 06/15/2021
|
DarioHealth Releases Study Demonstrating the Impact of Personalized Digital Interventions to Improve Self-Management of Diabetes
- Study results to be presented at the 14th International Conference on Advanced Technologies and Treatments for Diabetes NEW YORK, June 4, 2021 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO), a leader in the global digital therapeutics (DTx) market, announced today it will be presenting results of a new study at the 14th International Conference on Advanced Technologies and Treatments for Diabetes (ATTD 2021; June 2-5, 2021). The study, titled "Impact of Digital Intervention Engine on Diabetes Self-Management," examined the effect of DarioHealth's highly personalized digital journeys on both clinical and engagement outcomes, applying user-specific digital intervention flows for behavioral change to increase user digital engagement.
- 06/04/2021
|
DarioHealth Publishes Research Confirming the Impact of a Digital Therapeutic Platform and Live Coaching on Diabetes Outcomes
- NEW YORK,, May 27, 2021 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics market, today announced the publication of a new study through a Letter to the Editor in the Journal of Diabetes Science and Technology. The study is titled "Digital Therapeutics for Type 2 Diabetes: Incorporating Coaching Support and Validating Digital Monitoring.
- 05/27/2021
|
DarioHealth to Participate in the Virtual 18th Annual Craig-Hallum Institutional Investor Conference
- NEW YORK, May 26, 2021 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics market, today announced that management will participate in the 18th Annual Craig-Hallum Institutional Investor Conference, which is being held virtually on Wednesday, June 2. Erez Raphael, Chief Executive Officer, and Rick Anderson, President and General Manager of North America, will host investor 1x1 and small group meetings with registered attendees.
- 05/26/2021
|
DarioHealth Corp. (DRIO) CEO Erez Raphael on Q1 2021 Results - Earnings Call Transcript
- DarioHealth Corp. (DRIO) CEO Erez Raphael on Q1 2021 Results - Earnings Call Transcript
- 05/18/2021
|
DarioHealth Scoops Up Digital Behavioral Health Platform For $30M
- DarioHealth Corp (NASDAQ: DRIO) has agreed to acquire PsyInnovations Inc (dba wayForward), a behavioral health digital platform, for $30 million. wayForward is currently providing its full suite of digital behavioral health services to approximately 20,000 members and 20 self-insured employers.
- 05/18/2021
|
DarioHealth Acquires Digital Behavioral Health Platform wayForward
- NEW YORK, May 18, 2021 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics market, today announced it has entered into an agreement to acquire PsyInnovations, Inc. (dba wayForward), a behavioral health digital platform that includes AI-enabled screening to triage and navigate members to specific interventions, digital Cognitive Behavioral Therapy (CBT), self-directed care, expert coaching and access to in-person and telehealth provider visits. The wayForward platform fills an all too common hole in existing behavioral health coverage for people who may not need or be able to access provider-based treatment.
- 05/18/2021
|
DarioHealth Reports First Quarter 2021 Results and Operational Highlights
- NEW YORK, May 17, 2021 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics market, today reported financial results for the first quarter of 2021 and provided a corporate and commercial update. "During the first quarter, we delivered exceptional financial and operating results, driven by balanced contribution from organic growth and the acquisition of Upright Technologies, which we closed on February 2, 2021," stated Erez Raphael, Chief Executive Officer of Dario.
- 05/17/2021
|
DarioHealth to Report First Quarter 2021 Results on Monday, May 17
- NEW YORK, May 10, 2021 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics market, today announced it would release its financial results for the first quarter ended March 31, 2021 on Monday, May 17, 2021, after market close and host a conference call and webcast on Tuesday May 18, at 8:30 am Eastern Time. Erez Raphael, Chief Executive Officer, Rick Anderson, President and General Manager of North America, and Zvi Ben-David, Chief Financial Officer will host the call.
- 05/10/2021
|
DarioHealth Partners with MediOrbis on Virtual Care Offering for Diabetes
- NEW YORK, April 20, 2021 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics market, announced today the launch of a new virtual care initiative with MediOrbis, a telehealth provider specializing in chronic conditions. Eligible Medicare members who have diabetes can receive convenient virtual care for their diabetes, including telehealth delivered by MediOrbis and remote patient monitoring through DarioHealth's AI-powered digital chronic care platform under their existing Medicare benefit.
- 04/20/2021
|
DarioHealth Corp. (DRIO) CEO Erez Raphael on Q4 2020 Results - Earnings Call Transcript
- DarioHealth Corp. (DRIO) CEO Erez Raphael on Q4 2020 Results - Earnings Call Transcript
- 03/09/2021
|
A Preview Of DarioHealth's Earnings
- DarioHealth (NASDAQ:DRIO) releases its next round of earnings this Tuesday, March 09. Here is Benzinga's essential guide to DarioHealth's Q4 earnings report.
- 03/08/2021
|
DarioHealth to Report Fourth Quarter and Full Year 2020 Results on Tuesday, March 9
- NEW YORK, March 1, 2021 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics market, today announced it would release its financial results for the fourth quarter and full year ended December 31, 2020 on Tuesday, March 9, 2021, and host a...
- 03/01/2021
|
DarioHealth: Upright Acquisition A Game Changer
- Over the last couple of months, DRIO has continued to sign new contracts in each of its B2B channels, showing strong commercial momentum.
- 02/22/2021
|
DarioHealth to Participate in 10th Annual SVB Leerink Global Healthcare Conference
- NEW YORK, Feb. 19, 2021 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics (DTx) market, announced today that Erez Raphael, Chief Executive Officer, is scheduled to participate and host investor meetings at the 10th Annual SVB Leerink Global...
- 02/19/2021
|
DarioHealth Announces Acquisition of Leading Digital Musculoskeletal Company Upright Technologies and $70 Million Financing
- NEW YORK, Jan. 27, 2021 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics (DTx) market, announced today the signing of a definitive agreement to acquire digital musculoskeletal (MSK) company Upright Technologies Ltd. in a stock transaction....
- 01/27/2021
|
Glancy Prongay & Murray LLP Announces Investigation on Behalf of DarioHealth Corp.
- NEW YORK--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”) announces its investigation on behalf of DarioHealth Corp. (Nasdaq: DRIO) concerning the Company and its directors' and officers' possible violations of state laws. If you purchased DarioHealth stock, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Tom Kennedy, of GPM, 230 Park Avenue, Suite 530, New York, NY
- 01/07/2021
|
How To Predict Sales Growth
- I've found seven factors that correlate highly with future sales growth; this article explains each one.
- 09/08/2020
|
New Post From Your Neighbor
- How can I see the virtual labor day for,2020
- 09/07/2020
|
New Post From Your Neighbor
- FOOD PANTRY...
- 09/03/2020
|
New Post From Your Neighbor
- I dropped my wallet in Prospect Park today. If you found it,...
- 09/03/2020
|
New Post From Your Neighbor
- Hi Everyone, ...
- 09/02/2020
|
New Post From Your Patch Editor
- Hey Prospect Heights and Crown Heights! Patch is wondering,...
- 09/02/2020
|
New Post From Your Neighbor
- Why do developers think they can buy property in landmarked...
- 08/28/2020
|
The Daily Biotech Pulse: CureVac Close To Coronavirus Vaccine Deal With EU, Entera Bio's Positive Readout, Patent Protection For Co-Diagnostics
- Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 19)
10X Genomics Inc (NASDAQ: TXG)
ALX Oncology Holdings Inc (NASDAQ: ALXO)
Avenue Therapeutics Inc (NASDAQ: ATXI)...
- 08/20/2020
|
The Daily Biotech Pulse: Gilead's Filgotinib Stumbles With FDA, J&J Laps Up Momenta In $6.5B Deal, 2 IPOs
- Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 18)
Avenue Therapeutics Inc (NASDAQ: ATXI)
Checkmate Pharmaceuticals Inc (NASDAQ: CMPI)
DarioHealth Corp (NASDAQ:...
- 08/19/2020
|
DarioHealth Announces Poster Presentation at the Virtual Association of Diabetes Care and Education Specialists 2020 Annual Conference
- DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics market, today announced that an emerging science industry poster has been accepted for presentation at the virtual Association of Diabetes Care and Education Specialists (ADCES) 2020 Annual Conference, which is being held today, August 13, through August 16, 2020.
- 08/13/2020
|
New Post From Your Neighbor
- Room for Rent in Crown Heights Brooklyn....
- 08/13/2020
|
DarioHealth: Q2 Earnings Insights
- Shares of DarioHealth (NASDAQ:DRIO) moved higher by 2% in pre-market trading after the company reported Q2 results.Quarterly Results Earnings per share decreased 423.08% year over year to ($0.68), which beat the estimate of ($1.40).Revenue of $1,787,000 up by 8.24% from the same period last year, which beat the estimate of $1,550,000.Outlook DarioHealth hasn't issued any earnings guidance for the time being.Revenue guidance hasn't been issued by the company for now.Details Of The Call Date: Aug 12, 2020View more earnings on DRIOTime: 09:00 AMET Webcast URL: https://www.webcaster4.com/Webcast/Page/2224/36466Technicals 52-week high: $18.8452-week low: $0.20Price action over last quarter: Up 123.19%Company Profile DarioHealth Corp is a digital health company. It is engaged in the development and commercialization of patented and proprietary technology that provides consumers with laboratory-testing capabilities using smartphones and other mobile devices. The company's product, Dario Blood sugar monitor is a mobile, real-time, cloud-based, diabetes management solution based on a multi-featured software application combined with a blood glucose monitoring device. The group operates internationally and derives revenues from the sale of its Dario smart meter and related device-specific disposables test strip cartridges and lancets. The company generates the majority of the revenue by sales of its product.See more from Benzinga * Earnings Scheduled For August 12, 2020 * Stocks That Hit 52-Week Highs On Wednesday * Stocks That Hit 52-Week Highs On Friday(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
- 08/12/2020
|
DarioHealth Reports Second Quarter 2020 Results
- DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics market, today reported financial results for the second quarter 2020 and provided a corporate and commercial update.
- 08/12/2020
|
New Post From Your Neighbor
- Room for rent in Crown Heights Brooklyn....
- 08/12/2020
|
New Post From Your Neighbor
- Hi Everyone! I am selling delicious fresh pressed juices and...
- 08/11/2020
|
DarioHealth to Report Financial Results for the Second Quarter 2020 Results on August 12
- DarioHealth Corp. (Nasdaq: DRIO) ("DarioHealth" or the "Company"), a pioneer in the global digital therapeutics market, announced it will release its second quarter ended June 30, 2020 financial results on Wednesday, August 12, 2020, and host a conference call at 9:00am Eastern Time.
- 08/07/2020
|
The Daily Biotech Pulse: Novavax Vaccine Deals, Trevena Awaits FDA Decision, 2 IPOs
- Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 6)
ADiTx Therapeutics Inc (NASDAQ: ADTX) (announced introduction of AditxtScore for COVID-19 to be used in detecting...
- 08/07/2020
|
DRIO: Livongo and Teladoc to Merge
- By John Vandermosten, CFA NASDAQ:DRIO READ THE FULL DRIO RESEARCH REPORT Prior to the global pandemic, the world was increasingly moving towards the digital landscape. But when the coronavirus forced the world to isolate, it also increased global reliance on virtual interaction. Not only are companies like Amazon, Zoom and Netflix growing faster than ever as a result of changing consumer
- 08/06/2020
|
The Daily Biotech Pulse: FDA Nod For GlaxoSmithKline, Bristol-Myers Squibb Earnings, Acutus Medical IPO
- Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 5)
ABIOMED, Inc. (NASDAQ: ABMD)
Aerpio Pharmaceuticals Inc (NASDAQ: ARPO) (announced a U.S. government grant for a...
- 08/06/2020
|
New Post From Your Neighbor
- My roommate and I have a room for rent in Crown Heights...
- 08/05/2020
|
DarioHealth Announces $28.6 Million Private Placement
- DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics market, today announced that it closed a private placement transaction with accredited investors, including healthcare funds and institutions from the U.S. and Israel. The company received aggregate gross proceeds of approximately $28.6 million, before deducting placement agent fees and other offering expenses.
- 07/31/2020
|
DarioHealth Enters UK Remote Patient Monitoring (RPM) Market Through Agreement with Williams Medical
- DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics market, announced that the company has entered into a new strategic partnership with Williams Medical to make the DarioHealth Remote Patient Monitoring (RPM) digital therapeutics platform available to Healthcare Professionals (HCPs) across the United Kingdom and Ireland. Dario's turn-key RPM solution integrates the company's existing open platform, application technology, and the DarioEngage coaching platform, to allow Healthcare Professionals to monitor their patients remotely. Dario's digital solution is intended to provide relief for primary and secondary care providers challenged by the COVID-19 pandemic and facing potential serious winter pressures in the healthcare system. We believe that equipping practitioners to proactively treat, monitor and manage patients with long-term conditions within the community will ultimately result in reduction of the ongoing pressure on general practitioners, emergency departments, and in-patient services.
- 07/20/2020
|
DarioHealth Corp. (NASDAQ:DRIO) Insiders Increased Their Holdings
- We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. The...
- 07/16/2020
|
Dennis Matheis, President of Optima Health, a Multi-line Health Plan With More Than 850,000 Members and over 26,000 Providers, and Former President of Anthem Blue Cross and Blue Shield Central Region, Appointed to the Board of DarioHealth Corp | | IT Business Net
- NEW YORK, July 6, 2020 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics market, today announced that the company has appointed veteran health plan executi
- 07/06/2020
|
Dennis Matheis, President of Optima Health, a Multi-line Health Plan With More Than 850,000 Members and over 26,000 Providers, and Former President of Anthem Blue Cross and Blue Shield Central Region, Appointed to the Board of DarioHealth Corp
- DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics market, today announced that the company has appointed veteran health plan executive Dennis A. Matheis to its Board of Directors, effective July 2, 2020. Mr. Matheis brings to the Dario Board nearly 30 years of experience leading regional and national health care plans and related organizations. He currently serves as President of Optima Health, a division of Sentara Healthcare which has more than 850,000 members and a network of over 26,000 providers.
- 07/06/2020
|
Intersect ENT (NASDAQ:XENT) versus DarioHealth (NASDAQ:DRIO) Financial Review
- Intersect ENT (NASDAQ:XENT) and DarioHealth (NASDAQ:DRIO) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, earnings, analyst recommendations, valuation, profitability and risk. Institutional and Insider Ownership 87.7% of Intersect ENT shares are held by institutional investors. Comparatively, 8.4% […]
- 06/24/2020
|
Dario Health to Host Key Opinion Leader Call on Digital Therapeutics for the Management of Diabetes and Other Chronic Conditions
- DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics market, today announced that it will host a key opinion leader (KOL) call on digital therapeutics for the management of diabetes and other chronic conditions on Tuesday, June 23, 2020 at 10:30 a.m. Eastern Time.
- 06/18/2020
|
DarioHealth Announces Participation in the Virtual Going Digital: Behavioral Health Tech Summit
- DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics market, today announced that Omar Manejwala, M.D., Chief Medical Officer, will present at the virtual Going Digital: Behavioral Tech Summit. DarioHealth is also a sponsor of the event.
- 06/17/2020
|
DarioHealth (NASDAQ:DRIO) Receives News Impact Score of -3.53
- News articles about DarioHealth (NASDAQ:DRIO) have been trending very negative recently, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative press coverage by analyzing more than 6,000 news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five […]
- 06/16/2020
|
DarioHealth Presents New Studies Demonstrating Sustained Improvements in Blood Glucose and Blood Pressure Control in Users with Diabetes and Hypertension at the American Diabetes Association's 80th Scientific Sessions
- DarioHealth Corp. (Nasdaq: DRIO), a leading global digital therapeutics (DTx) company, presented the results of two new studies at the American Diabetes Association's (ADA) 80th Scientific Sessions that showed sustained improvements in blood glucose levels and blood pressure among users of its digital therapeutic platform for chronic diseases.
- 06/15/2020
|
DarioHealth Announces Two Remote Patient Monitoring (RPM) Agreements and Commences Enrollment
- DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics market, today announced that the company has signed its first two remote patient monitoring (RPM) agreements. Remote patient monitoring will allow treating physicians to continue to be the primary source of medical advice for patients in between office visits, potentially preventing unnecessary and unplanned hospital visits. Dario's RPM product integrates the company's existing open platform, application technology, and the DarioEngage coaching platform to provide physicians, health systems and large provider groups with a turnkey solution to leverage the recently approved remote patient monitoring codes. Effective January 2020, physicians can bill three new CMS approved RPM codes for Medicare members. In addition to improving the quality of care this can provide up to approximately $1,500 per patient per year in revenue to providers.
- 06/11/2020
|
Four big firms expected to enter the blue-chip FTSE 100 index
- B&Q owner Kingfisher and home repairs giant Homeserve are the other two business that are predicted to enter the share index.
- 06/04/2020
|
News Flash: 2 Analysts Think DarioHealth Corp. (NASDAQ:DRIO) Earnings Are Under Threat
- The analysts covering DarioHealth Corp. (NASDAQ:DRIO) delivered a dose of negativity to shareholders today, by making...
- 05/14/2020
|
Recap: DarioHealth Q1 Earnings
- Shares of DarioHealth (NASDAQ:DRIO) remained unaffected at $7.95 after the company reported Q1 results.Quarterly Results Earnings per share fell 946.67% year over year to ($1.57), which missed the estimate of ($0.75).Revenue of $1,667,000 less by 25.65% year over year, which missed the estimate of $1,750,000.Guidance DarioHealth hasn't issued any earnings guidance for the time being.Revenue guidance hasn't been issued by the company for now.How To Listen To The Conference Call Date: May 12, 2020View more earnings on DRIOTime: 08:04 PM ETWebcast URL: https://www.webcaster4.com/Webcast/Page/2224/34665Technicals Company's 52-week high was at $11.2552-week low: $0.20Price action over last quarter: Up 109.21%Company Overview DarioHealth Corp is a digital health company. It is engaged in the development and commercialization of patented and proprietary technology that provides consumers with laboratory-testing capabilities using smartphones and other mobile devices. The company's product, Dario Blood sugar monitor is a mobile, real-time, cloud-based, diabetes management solution based on a multi-featured software application combined with a blood glucose monitoring device. The group operates internationally and derives revenues from the sale of its Dario smart meter and related device-specific disposables test strip cartridges and lancets. The company generates the majority of the revenue by sales of its product.See more from Benzinga * Stocks That Hit 52-Week Lows On Monday * A Look Into AMC Entertainment's Price Over Earnings * Stocks That Hit 52-Week Highs On Monday(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
- 05/12/2020
|
DarioHealth Reports First Quarter 2020 Results
- DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics market, today reported financial results for the first quarter 2020 and provided a corporate and commercial update.
- 05/12/2020
|
The Daily Biotech Pulse: NASH Disappointment For Genfit, Novavax Lands $384M CEPI Funding For Coronavirus Vaccine, GW Pharma Earnings
- Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs May 11)
Acceleron Pharma Inc (NASDAQ...
- 05/12/2020
|
The Week Ahead In Biotech: Virtual Conference Presentations, Clovis PDUFA Date In The Spotlight
- The smid-cap biotech earnings deluge hit Wall Street in the week ended May 9, positively impacting the stocks in the sector. The iShares NASDAQ Biotechnology Index (NASDAQ: IBB)...
- 05/10/2020
|
DarioHealth Self-test Blood Glucose Meters Can Now Be Utilized Within Hospitals During the COVID-19 Pandemic Per Recently Issued Emergency FDA Guidelines
- DarioHealth Corp. (Nasdaq: DRIO), a global digital therapeutics (DTx) innovator, announced today that in an effort to reduce contact between healthcare providers and patients in hospital settings, limit COVID-19 exposure, and preserve personal protective equipment (PPE), the U.S. Food and Drug Administration (FDA) has recognized that home-use blood glucose meters including Dario's smartphone-connected metering device may be used by patients with diabetes who are hospitalized due to COVID-19 to check their own blood glucose levels and provide the readings to the health care personnel caring for them.
- 05/06/2020
|
DarioHealth poaches former Catasys execs, launches behavioral health coaching
- DarioHealth, a digital health company focused on patients with diabetes and hypertension, rolled out behavioral health coaching for its users.
- 05/05/2020
|
DarioHealth to Report Financial Results for the First Quarter 2020 Results on May 12
- DarioHealth Corp. (Nasdaq: DRIO) ("DarioHealth" or the "Company"), a pioneer in the global digital therapeutics market, announced it will release its first quarter ended March 31, 2020 financial results on Tuesday, May 12, 2020, and host a conference call at 8:30am Eastern Time.
- 05/05/2020
|
DarioHealth Expands Offering to Include Behavioral Health
- DarioHealth Corp. (Nasdaq: DRIO), a leading global digital therapeutics (DTx) innovator, announced today that it has expanded its offering on its chronic care platform application to include behavioral health coaching for stress, anxiety and loneliness, conditions which have recently escalated due to COVID-19 social distancing restrictions including "shelter-in-place" and "stay-at-home" orders.
- 05/04/2020
|
DarioHealth Expands Remote Care Offering With Integration of Full-Service Telemedicine
- DarioHealth Corp. (Nasdaq: DRIO), a pioneer in global digital therapeutics (DTx), announced today a new partnership with value-based telemedicine provider MediOrbis to expand Dario's existing service offering with a full suite of telemedicine capabilities for its 50,000 active users.
- 04/29/2020
|
U.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.13%
- U.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.13%
- 04/28/2020
|
Can DarioHealth (NASDAQ:DRIO) Afford To Invest In Growth?
- There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
- 04/18/2020
|
Edited Transcript of DRIO earnings conference call or presentation 17-Mar-20 12:30pm GMT
- Q4 2019 DarioHealth Corp Earnings Call
- 04/06/2020
|
DarioHealth® Announces Key New Hires Expanding Its Management Depth in the Employer and Managed Care Markets
- DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics market, announced today the appointment of Omar Manejwala, M.D to the newly created position of Chief Medical Officer, and Barbara Stark as Senior Vice President and Head of Managed Markets. These two appointments provide decades of industry and clinical experience to the managed care and clinical support teams.
- 03/26/2020
|
Reviewing DarioHealth (NASDAQ:DRIO) & Atrion (NASDAQ:ATRI)
- DarioHealth (NASDAQ:DRIO) and Atrion (NASDAQ:ATRI) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, valuation, institutional ownership, analyst recommendations, profitability, risk and earnings. Insider and Institutional Ownership 12.7% of DarioHealth shares are held by institutional investors. Comparatively, 65.8% of Atrion […]
- 03/26/2020
|
Dario Diabetes Management Is Recognized as a Leading Application for Children/Young People Self-managing Healthcare During COVID-19 Pandemic
- DarioHealth Corp. (NASDAQ: DRIO), a global digital therapeutics (DTx) innovator, announced today an endorsement from the U.K. based ORCHA, highlighting the Company's Diabetes Management Application as being suitable and safe for children and young people. In its recommendation, ORCHA mentioned the value of Dario's app in helping parents monitoring their child's diabetes information. The ORCHA team is part of NHS England's National Innovation Accelerator program and supports many NHS and local government organizations to drive the uptake of digital health among their populations.
- 03/25/2020
|
DarioHealth Enters Into a Partnership With Vitality to Accelerate Penetration Into the Self-insured Employer Market
- DarioHealth Corp. (Nasdaq: DRIO) ("Dario") a pioneer in the global digital therapeutics market, announced today that it has entered into a partnership with Vitality Group, a global health and wellness company committed to making people healthier. Under the partnership, Vitality will integrate Dario's digital therapeutics for chronic conditions into its current wellness solution platform and co-market the Dario solution to Vitality's existing client base. In conjunction with the partnership, Dario granted Vitality warrants that will become exercisable dependent on the success of the partnership over the next four years, beginning in 2020.
- 03/24/2020
|
The Daily Biotech Pulse: Mylan Ramps Up Manufacturing Of Potential COVID-19 Drug, Lexicon Stops Study Early, Masimo To Buy German Ventilation Company
- Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech stocks that hit 52-week highs March 19.) * Biomerica, Inc. (NASDAQ: BMRA) * Centogene NV (NASDAQ: CNTG) * Gilead Sciences, Inc. (NASDAQ: GILD) * Imara Inc (NASDAQ: IMRA) * Regeneron Pharmaceuticals
- 03/20/2020
|
The Daily Biotech Pulse: Mylan Ramps Up Manufacturing Of Potential COVID-19 Drug, Lexicon Stops Study Early, Masimo To Buy German Ventilation Company
- Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech stocks that hit 52-week highs March 19.)
Biomerica, Inc. (NASDAQ...
- 03/20/2020
|
DarioHealth Reports Fourth Quarter and Year End 2019 Results
- DarioHealth Corp. (Nasdaq: DRIO), a global digital therapeutics (DTx) innovator, today reported financial results for the fourth quarter and full year ended December 31, 2019 and provided a corporate and commercial update.
- 03/17/2020
|
The Week Ahead In Biotech: COVID-19 Updates, Tapering Earnings Flow, Eton's Seizure Drug Review
- The biopharma space bled along with the rest of the market and COVID-19 levered biotechs weren't spared either.Biogen Inc (NASDAQ: BIIB) was in the news for all wrong reasons, as an employee conference held by the company in Boston from Feb. 24 to 27 was blamed for 77 of the 95 COVID-19 cases reported
- 03/15/2020
|
The Week Ahead In Biotech: COVID-19 Updates, Tapering Earnings Flow, Eton's Seizure Drug Review
- The biopharma space bled along with the rest of the market and COVID-19 levered biotechs weren't spared either.
Biogen Inc (NASDAQ: BIIB) was in the news for all wrong...
- 03/15/2020
|
DarioHealth to Host Fourth Quarter 2019 Conference Call March 17, 2020
- Global digital therapeutics innovation leader DarioHealth Corp. (NASDAQ: DRIO) today announced it will release its fourth quarter and year end 2019 results on Tuesday, March 17, and host a conference call the same morning at 8:30 am EDT.
- 03/12/2020
|
DarioHealth Appoints Two New Board Members
- DarioHealth Corp. (NASDAQ: DRIO), a pioneer in the global digital therapeutics market, announced today the company has appointed Yadin Shemmer and Adam K. Stern to serve as board members effective immediately until the 2020 Annual Meeting of stock holders.
- 03/05/2020
|
Those Who Purchased DarioHealth (NASDAQ:DRIO) Shares Five Years Ago Have A 90% Loss To Show For It
- Long term investing is the way to go, but that doesn't mean you should hold every stock forever. We don't wish...
- 03/04/2020
|
DarioHealth Digital Diabetes Management System is Now Available at Albertsons
- DarioHealth Corp. (NASDAQ: DRIO), a pioneer in the global digital therapeutics market, announced today the launch of its digital therapeutics solution for managing chronic diseases such as diabetes and hypertension on Albertsons Marketplace.
- 02/24/2020
|
DarioHealth® Presents New Clinical Study Outcomes Showing the Dario Digital Therapeutics Platform Helps Insulin Dependent Patients With Diabetes Better Manage Their Chronic Condition
- DarioHealth Corp. (Nasdaq: DRIO) ("DarioHealth" or "Dario"), a pioneer in the global digital therapeutics market, today presented a new clinical study at the Advanced Technologies & Treatments for Diabetes ("ATTD") conference in Madrid, Spain, which showed significant reductions of both hypoglycemic and high glycemic events in people with type 1 and insulin dependent type 2 diabetes using Dario's digital therapeutics platform. The presentation will be available at the conference, on the ATTD 2020 website during the conference, and online for one year following the conference. The accepted abstract will be published in the peer-reviewed journal Diabetes Technology & Therapeutics.
- 02/19/2020
|
DarioHealth Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- DarioHealth Corp. (Nasdaq: DRIO) ("DarioHealth" or the "Company"), a pioneer in the global digital therapeutics market, announced today that on January 30, 2020, Richard Anderson was granted a non-qualified stock option award to purchase 90,000 shares of the Company's common stock, as well as an additional non-qualified performance-based stock option award to purchase an additional 90,000 shares of the Company's common stock, pursuant to Nasdaq Listing Rule 5635(c)(4) outside of the Company's existing equity compensation plans in connection with Mr. Anderson's previously-announced employment by the Company as its President and General Manager of North America. These options were granted as an inducement material to Mr. Anderson becoming an employee of the Company, in accordance with Nasdaq Listing Rule 5635(c)(4).
- 01/31/2020
|
Israeli digital therapeutics company raises $21.3M for U.S. expansion
- Publicly-traded DarioHealth plans to use the cash to put its smartphone-based glucometer into the hands of insurers.
- 12/20/2019
|
